Evidence map›Paper›PMID 39574700›Full record

ArticlebioRxiv : the preprint server for biology2025

F2,6BP restores mitochondrial genome integrity in Huntington's Disease.

Anirban Chakraborty, Santi M Mandal, Mikita Mankevich, Rajam S Mani, Shandy Shahabi, Tapan Biswas, Manohar Kodavati, Sravan Gopalkrishnashetty Sreenivasmurthy, Nisha Tapryal, Balaji Krishnan and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Anirban ChakrabortyDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Santi M MandalDepartment of Chemistry and Biochemistry, University of California San Diego, LA Jolla, California 92093, USA.
Mikita MankevichDepartment of Chemistry and Biochemistry, University of California San Diego, LA Jolla, California 92093, USA.
Rajam S ManiDepartment of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada.
Shandy ShahabiDepartment of Chemistry and Biochemistry, University of California San Diego, LA Jolla, California 92093, USA.
Tapan BiswasDepartment of Chemistry and Biochemistry, University of California San Diego, LA Jolla, California 92093, USA.
Manohar KodavatiDepartment of Neurosurgery, Center for Neuroregeneration, The Houston Methodist Research Institute, Houston, Texas 77030, USA.
Sravan Gopalkrishnashetty SreenivasmurthyDepartment of Neurology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Nisha TapryalDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Balaji KrishnanDepartment of Neurology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Muralidhar L HegdeDepartment of Neurosurgery, Center for Neuroregeneration, The Houston Methodist Research Institute, Houston, Texas 77030, USA.ORCID 0000-0001-7333-8123
Michael WeinfeldDepartment of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada.
Gourisankar GhoshDepartment of Chemistry and Biochemistry, University of California San Diego, LA Jolla, California 92093, USA.
Tapas HazraDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA.

Funding

Michigan Alzheimer's Disease Core CenterP30AG053760 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIEBERMAN, ANDREW P · 2016 to 2020
$10.1M
Preferential single-strand break repair in the active genes of mammalian cellsR01NS073976 · NINDS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAZRA, TAPAS K · 2012 to 2021
$3.3M
Suppressing Inflammation by Blocking IKK OligomerR01AI163327 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GOURISANKAR GHOSH · 2022 to 2026
$2.6M
Defining the altered FUS-PARP-1-DNA Ligase III axis and its implications to nuclear and mitochondrial genome damage response in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)RF1NS112719 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HEGDE, MURALIDHAR L · 2020 to 2020
$2.0M
Phospholipase D1 Mediated Early Events Affecting Synaptic Dysfunction in Alzheimer's Disease and Related DementiaR01AG063945 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KRISHNAN, BALAJI · 2020 to 2024
$2.0M
DNA double strand break repair deficiency and neurodegenerationR56NS073976 · NINDS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAZRA, TAPAS K · 2024 to 2024
$536k
Synaptic PLD1 Levels/Signaling is Elevated Through Epigenetic Regulation in the CNS of AD Patients as a Function of Disease Severity and Cognitive DeclineR21AG059223 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KRISHNAN, BALAJI · 2018 to 2019
$434k
Chromogranin A is an aging risk factorR21AG078635 · NIA · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GHOSH, GOURISANKAR, MAHATA, SUSHIL K · 2023 to 2024
$413k
NIAID NIH HHS R01 AI163327NIA NIH HHS P30 AG053760NIA NIH HHS R01 AG063945NIA NIH HHS R21 AG059223NIA NIH HHS R21 AG078635NINDS NIH HHS R01 NS073976NINDS NIH HHS R56 NS073976NINDS NIH HHS RF1 NS112719
6 · The paper itself

Abstract

Several reports have indicated that impaired mitochondrial function contributes to the development and progression of Huntington's disease (HD). Mitochondrial genome damage, particularly DNA strand breaks, is a potential cause for its compromised functionality. Here we show that the activity of polynucleotide kinase 3'-phosphatase (PNKP), a critical DNA end-processing enzyme, is significantly decreased in the mitochondrial extract of HD patients' brains due to a lower level of fructose-2,6 bisphosphate (F2,6BP), a biosynthetic product of 6-phosphofructo-2-kinase fructose-2,6-bisphosphatase 3 (PFKFB3). Such decrease in PNKP activity leads to persistent DNA strand breaks that are refractory to subsequent steps for repair completion. Both PFKFB3 and F2,6BP, an allosteric modulator of glycolysis, are also present in the mitochondria and PFKFB3 is part of a mitochondrial DNA repair complex containing HTT, PNKP, DNA Pol γ (POLG) and Lig IIIa. Notably, PNKP binds F2,6BP (Kd= 525±25 nM) and utilizes it as a cofactor. The levels of both F2,6BP and PFKFB3 are significantly decreased in the mitochondrial extract of HD mouse striatal neuronal cells and patients' brain. Activity of PNKP is thus severely decreased in the mitochondrial extract; however, addition of F2,6BP restored its activity. Moreover, supplementation of F2,6BP in HD cells restored PFKFB3 level, mitochondrial genome integrity and partially restored mitochondrial membrane potential, mitochondrial respiration and prevented pathogenic aggregate formation. We also observed that supplementation with F2,6BP restored mitochondrial genome integrity in an HD

Indexed as

DNA strand break repairfructose-2,6-bisphosphateHuntington’s diseasemitochondriaPNKP

Identifiers

PMID39574700
PMCPMC11580889

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.